Reprint

Advances in Cancer Multimodal Approach: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies

Edited by
August 2024
342 pages
  • ISBN978-3-7258-1843-3 (Hardback)
  • ISBN978-3-7258-1844-0 (PDF)

This is a Reprint of the Special Issue Advances in Cancer Multimodal Approach: Biomarkers, Mechanisms, Surgical Procedures and Oncological Therapies that was published in

Biology & Life Sciences
Medicine & Pharmacology
Public Health & Healthcare
Summary

Cancer is the leading cause of death worldwide, accounting for more than 10 million deaths each year and an even larger number of patients who are diagnosed with this disease and have to undergo various procedures. All of this has happened following the increased number of risk factors that have impacted our lives over the past few decades, such as tobacco use, obesity and different unhealthy diets, alcohol consumption, viral infections, and exposure to certain chemicals or radiation. Our goal as medical practitioners or scientists is to obtain the best outcome for our patients, from prophylactic procedures to a correct diagnosis, specific multimodal treatment, and rigorous follow-up. All of these factors have significantly improved in the last few years because of a better understanding of the genetic and molecular mechanisms of cancer development, the emergence of new technologies in cancer detection or surgical techniques, and breakthroughs in oncological therapies. However, there remains a huge field to explore, considering the current unknowns and the alert dynamics under which cancer evolves. Oncology is the medical field that requires the mobilization of most medical specialties in order to outline the particular profile of each individual patient and optimize the necessary treatment.

Format
  • Hardback
License and Copyright
© 2024 by the authors; CC BY-NC-ND license
Keywords
interstitial cells of Cajal; cancer; gastrointestinal tumors; c-kit; n/a; cancer; comprehensive nursing service; outcome; prognostic factors; prognostic score; ovarian carcinoma; adenocarcinoma; gastric cancer; MKN-45; cisplatin; magnolol; parathyroid carcinoma; secondary hyperparathyroidism; hypercalcemia; brain metastases; lung hepatoid adenocarcinoma; K-RAS; liquid biopsy; ddPCR; pediatric cancer; two-dimensional gel electrophoresis; MS-based proteomics; metabolomics; pharmacokinetics of anticancer drugs; epigenetics; chromatin modifications; acute lymphoblastic leukemia; Philadelphia chromosome; relapse; allogeneic stem cell transplantation; cancer; colorectal; obstruction; cervical cancer; HPV; nerve-sparing radical hysterectomy; radiochemotherapy; checkpoint inhibitors; CD34; regenerative stem cell; cancer stem cells; adjuvant chemotherapy; neoadjuvant radiotherapy; neoadjuvant radiochemotherapy; rectal cancer; tumor downstage; Romanian oncologists; hepatocellular carcinoma; radiofrequency ablation; salvage hepatectomy; laparoscopic liver resection; rhabdomyosarcoma; spindle cell; inguinal; hernia; adult; rectal cancer; radiotherapy; DNA; neoadjuvant therapy; prognosis; pain; neoplasm; non-invasive brain stimulation; repetitive transcranial magnetic stimulation (rTMS); transcranial direct current stimulation (tDCS); cranial electric stimulation (CES); hemoglobin to red cell distribution width; Hb/RDW ratio; cancer; risk assessment; DNA damage response; germline mutation; localized prostate cancer; next-generation sequencing; radiomics; radiotherapy; head and neck cancer; lymph node; breast cancer; biomarkers; serological; histological; translational medicine; rectal cancer; neoadjuvant therapy; total neoadjuvant therapy; chemoradiotherapy; tumor stage; HPV; PCR; p16INK4a; immunohistochemistry; NSCLC; Jordan; breast cancers; neoadjuvant chemotherapy; breast cancer subtype; biomarker; p53; prognostic factor; cervical cancer; lymph node; downstaging; neoadjuvant treatment; adenopathy